The ability of Biota to safeguard its IPs is also a big worry.
Too much focus on product research and development, little on strategic plan. That is how the previous management failed us.
By the way, It is not impossible for other pharma to pick Biota's compound and gets success out of it.
- Forums
- ASX - By Stock
- BTA
- strategic review out
strategic review out , page-11
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
Previous Video
Next Video
SPONSORED BY The Market Online